comparemela.com

Latest Breaking News On - Rafael pharma - Page 1 : comparemela.com

Smaller biotechs making big advances

GlycoMimetics, Inc. (GLYC) CEO Harout Semerjian on Q1 2022 Results - Earnings Call Transcript

GlycoMimetics, Inc. (NASDAQ:NASDAQ:GLYC) Q1 2022 Results Conference Call April 28, 2022 08:30 AM ET Company Participants Shari Annes - IR Harout Semerjian - CEO Brian Hahn - CFO Armand.

New-york
United-states
Australia
Canada
Harout-semerjian
Shari-annes
Armand-girard
Brian-hahn
Rafael-pharma
Red-white
Zegbeh-jallah
Company-participants

GlycoMimetics (GLYC) Q1 2022 Earnings Call Transcript

Rafael Holdings Reports Third Quarter Fiscal Year 2021 Results

Rafael Holdings Reports Third Quarter Fiscal Year 2021 Results
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United-states
Israel
Israeli
American
Fordoz-pharma
Howard-jonas
Rafael-pharma
Third-party
American-society-of-clinical-oncology
Lipomedix-pharmaceuticals-ltd
Rafael-pharmaceuticals
Rafael-holdings-inc

Old West: "Investment in Rafael Holdings (RFL) Represents an Extremely Asymmetric Opportunity"

Old West: “Investment in Rafael Holdings (RFL) Represents an Extremely Asymmetric Opportunity” Old West Investment Management, an investment management firm, published its first quarter 2021 investor letter – a copy of which can be downloaded here. An average  return of 25% was delivered by the fund for the Q1 of 2021, ahead of its S&P 500 benchmark that delivered a 6% return for the same period. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021. Old West Investment Management, in their Q1 2021 investor letter, mentioned Rafael Holdings, Inc. (NYSE: RFL), and shared their insights on the company. Rafael Holdings, Inc. is a Newark, New Jersey-based clinical-stage oncology pharmaceutical company that currently has a $682.7 million market capitalization. Since the beginning of the year, RFL delivered an impressive 76.72% return, extending its 12-month gains to 192.06%. As of April 28, 2021, the stock closed at $41.38 per share.

Taiwan
Japan
South-korea
Howard-jonas
Sanjeev-luther
Alberto-gabizon
Kalinovskiy-shutterstock
Sol-barer
Chi-van-dang
Rafael-pharma
Richard-axel
Rafael-pharmaceuticals

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.